Interview with Dr Louise Emmett for UroToday
Copper-67 vs lutetium-177 manufacture
Interview with Dr Alan Taylor and Dr Oliver Sartor for UroToday
Interview with Dr Alan Taylor and Michael Frazis for Frazis Capital Partners
Dr Geoffrey Johnson on the SECuRE trial with 64/67Cu-SAR-bisPSMA for GU Oncology Now
Treatment of mCRPC patient with 2 cycles of 67Cu-SAR-bisPSMA (8GBq) leads to undetectable PSA level
Copper-67 production
SAR-bisPSMA – a next-generation radiopharmaceutical for prostate cancer diagnosis and treatment
ShareCafe’s “Hidden Gems” Webinar